![Courtenay C. Brinckerhoff, intellectual property law attorney, Foley & Lardner Law Firm](https://www.natlawreview.com/sites/default/files/styles/author_profile/public/images/CB.jpg?itok=8avFnppT)
Courtenay Brinckerhoff is a partner and intellectual property lawyer with Foley & Lardner LLP. Ms. Brinckerhoff’s practice focuses on client counseling in all aspects of obtaining, licensing and enforcing patents and conducting freedom-to-operate and due diligence investigations. She is chair of the firm’s IP Law and Practice committee, immediate past vice chair of the firm’s Chemical, Biotechnology & Pharmaceutical Practice and a member of the firm's Patent Trials group, Appellate Practice and Life Sciences Industry Team. She also is involved with Foley’s Medical Device Initiative and Nutraceuticals Team. Ms. Brinckerhoff is the editor and primary author for Foley’s PharmaPatentsBlog.com.
Over the past 20 years, Ms. Brinckerhoff has represented clients before the U.S. Patent Office, the Patent Trial and Appeal Board, and the U.S. Court of Appeals for the Federal Circuit, and has been involved in complex patent matters, including a four-party interference, Inter Partes Reexaminations, Inter Partes Reviews, and ANDA litigation.
Ms. Brinckerhoff works with clients in diverse industries, including pharmaceuticals (chemical and biotechnological), human and animal food products, nutraceuticals, and medical devices. She has particular experience with transdermal pharmaceutical products (patches, gels, and liquids), oral dosage forms (including controlled/extended release formulations), enzyme-based technologies, diagnostic and therapeutic antibodies, active and passive immunization therapies, and personalized medicine.
She has served as vice chair of the firm’s Chemical, Biotechnology & Pharmaceutical Practice and is an active member of the firm's Appellate Practice and Life Sciences Industry Team.
More Legal and Business Bylines From Courtenay C. Brinckerhoff
- Amicus Briefs On Biosimilar Patent Litigation - (Posted On Thursday, April 23, 2015)
- An In-Depth Look At USPTO Patent Quality Problems - (Posted On Tuesday, April 21, 2015)
- Stricter Standing For Inter Partes Review? - (Posted On Tuesday, April 14, 2015)
- Apotex Has Standing Despite Benicar Patent Disclaimer - (Posted On Thursday, April 09, 2015)
- Waiting On Sequenom: Pharma Patents - (Posted On Tuesday, April 07, 2015)
- No Collateral Challenge Of Patent Application Revival - (Posted On Tuesday, March 31, 2015)
- Patent Term Adjustment In The Post-RCE Period -- Request for Continued Examination - (Posted On Thursday, March 26, 2015)
- California Federal Judge Finds Biosimilar Patent Procedures Optional - (Posted On Monday, March 23, 2015)
- The Remicade Biosimilar Patent Dispute - (Posted On Tuesday, March 10, 2015)
- STRONG Patents Act Would Fix Micro Entity Gap - (Posted On Thursday, March 05, 2015)
Courtenay C. Brinckerhoff and her work on Foley & Lardner's Pharma Patents blog has been selected for a National Law Review Go-To Thought Leadership Award. Ms. Brinckerhoff offers expert analysis on an area of law that can be very complicated, breaking down developments at the U.S. Patent Office, the Patent Trial and Appeal Board, and the U.S. Court of Appeals for the Federal Circuit. Her insights on patent litigation, especially pharmaceutical patents, and how decisions impact the larger landscape are of particular interest to our readers. You can subscribe to Foley & Lardner's blog, PharmaPatents, here.